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Abstract 
This overview considers the opportunities and challenges that face the use of gluco-
regulatory peptides to treat type 2 diabetes.  New insulin analogues and formulations are 
being developed with pharmacokinetic properties to speed-up or prolong transfer from a 
subcutaneous injection site to the target tissues, or to selectively favour effects on the liver. 
Alternative routes of insulin administration continue to attract attention, and advances in the 
integration of glucose monitoring with insulin pump devices are improving miniaturised 
‘closed loop’ artificial pancreas systems.  Proof of concept has been established for non-
cellular glucose-responsive insulin delivery (‘smart insulins’) to release insulin from implants 
or circulating depots in proportion to circulating glucose.  The many peptides involved in 
blood glucose control offer diverse therapeutic opportunities.  Exploitation of multiple 
selected receptor targets using constructs of hybrid and chimeric peptides, especially those 
based on glucagon and gastrointestinal hormones, has gained much credence from initial 
preclinical studies.  Peptide templates identified from comparative endocrine studies have 
also provided valuable insights in this respect and indicated novel approaches to address 
associated conditions such as obesity and infections at the same time.  Nevertheless, there are 
many challenges to the use of therapeutic peptides that impose on every step in the complex 
pathway from design and testing through to making a fully characterised therapeutic product, 
and optimising administration, tissue targeting and degradation.  Stability of peptides and 
immunological uncertainties of novel structures require particular consideration as well as the 
need to avoid over-reduction of blood glucose into hypoglycaemia.         
 
 
 
 
Introduction 
Hormonal peptides play a decisive role in the control of blood glucose homeostasis from the 
activation of feeding behaviour and the intestinal digestion of carbohydrates through to the storage, 
mobilisation and utilisation of glucose as a vital source of energy.  Blood glucose concentrations are 
normally maintained within a narrow range of 4-9 mmol/L, due mostly to peptide hormones that 
balance fluctuations in the prandial supply and tissue storage of nutrients with the varied demands of 
normal metabolism and the extremes of exercise and fasting.  Excess glucose accumulates in the liver 
and muscle as glycogen or is converted to triglyceride in adipose tissue, and the liberation of these 
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nutrient stores is highly regulated.  Low blood glucose concentrations (hypoglycaemia) below about 3 
mmol/L cause symptoms of neuroglycopenia and concentrations below 2 mmol/L can be fatal.  
Conversely, exposure to high circulating glucose concentrations (hyperglycaemia) above about 10-12 
mmol/L causes glucosuria, osmotic diuresis and risk of dehydration, while persistent hyperglycaemia 
(diabetes) causes glucotoxic damage to the endothelium of capillaries which typically manifests as 
nephropathy and retinopathy as well as nerve cell damage responsible for neuropathies.  Glucotoxic 
damage to the endothelium in large vessels also contributes to the long-term increased risk of 
cardiovascular disease in type 2 diabetes [1].   
The persistent hyperglycaemia of diabetes is predominantly due to defects in the secretion and/or 
action of insulin, but many other regulatory peptides are intimately involved, especially with type 2 
diabetes.  Lack of insulin and impaired insulin action (insulin resistance) deprive major insulin-
sensitive tissues such as active skeletal muscle of adequate glucose.  Inadequate insulin is also 
responsible for unrestrained output of glucose by the liver and fatty acids released from adipose 
tissue, resulting in the elevated concentrations of these nutrients in the circulation.  Beyond disruption 
of insulin-glucose dynamics, altered production, secretion and activity of many other peptide 
hormones contribute to the metabolic disturbances and the pathogenic sequelae in diabetic states.  
These include other pancreatic hormones and regulatory peptides of the alimentary tract, other neuro-
endocrine glands, adipose tissue and further peptide-secreting tissues [Table 1].   This chapter will 
focus on the breadth of opportunities and the challenging constraints for peptide therapies in the 
management of hyperglycaemia in type 2 diabetes. 
  
Glycaemic control in type 2 diabetes 
Whereas type 1 diabetes is necessarily dominated by the insulinopenic effect of near total 
autoimmune beta cell destruction and the need for life-preserving delivery of insulin replacement 
therapy, type 2 diabetes attracts a wider variety of therapeutic approaches to address its multiple 
causes and its variable progression (Figures 1 and 2) [2, 3].  These approaches include treatments to 
improve insulin action or other manoeuvres to reduce demands on insulin secretion or increase beta 
cell function.  They also include stimulation of insulin secretion and more physiological delivery of 
exogenous insulin, as well as suppression of hormones that normally raise blood glucose 
concentrations.  The underlying purpose of these approaches is to reinstate glycaemic control to as 
near normal as practicable, safe and comfortable for the patient in order to relieve acute symptoms, 
minimise the impact of glucotoxic microvascular complications, and lessen the compounding 
detrimental effects of insulin resistance, glucotoxicity, lipotoxicity and other metabolic aberrations on 
cardiovascular risk in type 2 diabetes.     
4 
 
When evaluating strategies to improve glycaemic control it is appreciated that the severity of insulin 
resistance in type 2 diabetes can often require several times the normal physiological amount of 
insulin to achieve near normal blood glucose concentrations.  Although interventions to raise insulin 
concentrations are necessary when insulin concentrations are severely depleted, stimulating insulin 
secretion is not always possible or ideal because high concentrations of insulin promote the down 
regulation of insulin receptors and accentuate lesions in the post-receptor pathways of insulin action  
[4, 5].  Also, excess insulin causes weight gain, mostly as extra adipose deposition which further 
aggravates insulin resistance, and over insulinisation can precipitate episodes of hypoglycaemia.  
Hence alternatives to insulin can be advantageous in the treatment of type 2 diabetes to reduce insulin 
requirements, and combinations of differently acting agents can be used to address different facets of 
the disease.  Thus the many different peptides involved in glucose regulation provide potential targets 
and templates for a breadth of therapeutic approaches.  
Opportunities to improve insulin delivery 
The administration of insulin in advanced insulinopenic states of type 2 diabetes is usually initiated by 
subcutaneous injection of once-daily or twice-daily long-acting or intermediate-acting insulin to 
provide an approximately consistent basal concentration.  This may be supplemented if required with 
additional (bolus) amounts of a short-acting or rapid-acting insulin to coincide with meals, similar to 
the normal pattern of endogenous insulin secretion [6].  A recent refinement to create an even faster 
rapid-acting insulin (Fiasp) is a formulation that includes nicotinamide to improve absorption and 
arginine as a stabilizing agent.  Regarding longer acting insulins, refinements under investigation to 
prolong circulating half-life include linkage to polyethylene glycol (PEGylation) and modified fatty 
acid linkage to albumin, enabling more consistent day profiles of plasma insulin with more 
predictable glycaemic control and fewer ‘hypos’.  As patents on existing insulin analogues expire, 
copies of these insulins (biosimilar insulins) are set to emerge.  Abasaglar is a recently introduced 
copy of the long-acting insulin glargine.  It is pertinent to note that although biosimilars are intended 
to be similar to existing products but they are unlikely to be exact replicas:  the  manufacturing 
process involves living organisms which can vary, the isolation and formulation processes may be 
slightly different and the final products are therefore unlikely to be identical to their reference 
products. Hence, switching between products may require dose adjustment [7, 8].   
For the last thirty years the strength of insulin preparations has been unified to 100 units per ml, where 
1 unit of insulin glucose-lowering activity is equivalent to 37.5 ug (6  nmol) of pure natural human 
insulin.  This conformity was introduced to reduce the risk of medication errors which occurred when 
insulin was available in various different strengths, the only exception being a 500 units per ml 
strength for special high-dose requiring circumstances.   Now we are seeing a re-emergence of 
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different strengths of insulins at 100, 200, 300, 400 and 500 units per ml.  In most western countries 
insulin is now largely delivered with pen injectors where an exact dose is selected using a digital dial, 
but use of an ordinary syringe to extract the dose from a vial of insulin is still undertaken by 
healthcare professionals in hospitals and by patients in many parts of the world, requiring extra 
caution against dosage errors. 
To reduce the frequency of basal insulin injections from once or twice daily to once weekly or once 
monthly, several possible very slow release insulin depots are being tested.  These include a 
subcutaneous depot of microspheres containing 5-kDa PEGylated human insulin lasting for a week 
and a heat-sensitive PEG-based subcutaneously injected biodegradable polymer that forms a gel at 
body temp and releases insulin from a depot of chitosan-zinc-insulin over a month [8, 9].   
Tissue-selective insulin 
A particular limitation of subcutaneously administered insulin by injections and pumps is that it does 
not target the liver with higher concentrations than the periphery as occurs under physiological 
circumstances with the release of insulin from the pancreas into the portal circulation.   To provide 
proportionally more insulin to the liver than to muscle or adipose tissue, insulin analogues have been 
linked to selected sizes of PEG (eg insulin lispro coupled to a 20-kDa PEG).  While this prolongs 
circulation time it also enables the molecules to penetrate the wide fenestrations of the sinusoidal 
endothelium in the liver but reduces access to muscles and fat [10].  Although a preferential hepatic 
action was achieved this particular molecule has not progressed in development.   
Alternatives to injections 
To overcome the inconvenience of bolus meal-time injections, inhaled insulins (eg Exubera and 
Afrezza) have been well developed to administration of small quantities of insulin for rapid 
absorption.  However, low bioavailability, high cost and concerns about dose accuracy and possible 
adverse effects on the lungs have resulted in discontinuation [11].  However, a buccal spray 
preparation of insulin (Oral-Lyn) is available in some countries to conveniently deliver small prandial 
doses of insulin, but development of nasal sprays have been limited by variable bioavailability and 
damage to the nasal epithelium by absorption enhancers [12].   
Oral delivery is possible for gradual administration of a basal insulin, and many different types of oral 
preparations have been evaluated, but bioavailability is generally low and often inconsistent.  
Approaches include various forms of encapsulation from liposomes to nanoparticles, and the use of 
absorption enhancers such as sodium-chlorosalicyloyl-aminobutyrate (CNAB).   The difficulties are 
well rehearsed, notably peptidase degradation and pH sensitivities, as well as transfer from lumen to 
venous or lymphatic drainage, the latter running the gauntlet of Peyer’s patches and slow transit to the 
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circulation [12-14].   Sometimes forgotten is the potential for unabsorbed bioactive insulin to generate 
unwanted effects in the colon [15].           
Pumps and implants 
An account of insulin pump technologies is beyond the scope of this review, but it is 
appreciated that controlled subcutaneous or intravenous delivery of insulin by programmable 
pumps with manual over-ride is well established [16].  Various closed-loop versions that take 
advantage of advances in glucose monitoring and dose-calculation software to automatically 
adjust insulin dose have been successfully trialled in type 1 diabetes [17, 18].  Discretely 
concealed patch pumps attached to the skin are gaining application for open- and closed-loop 
systems: the patch comprises a small refillable or replaceable insulin reservoir and a small 
remotely controlled pump to deliver the insulin subcutaneously via a cannula hidden beneath 
[19, 20].   
A review of live tissue approaches to insulin delivery using isolated islets, cultured beta-cells, 
differentiated insulin-secreting stem cells and gene therapy manipulations is also beyond the 
bounds of the present article and these aspects are recently comprehensively reviewed 
elsewhere [21-23]. An interesting novel approach demonstrated in diabetic mice has used an 
implant of optogenetically engineered insulin-secreting cells that are activated by implanted 
light-emitting diodes and controlled via a smartphone in response to signals from a glucose 
monitor and remote computer [24].  This illustrates the potential of bioengineering to harness 
advances in electrical and communication technologies together with genetic and 
implantation technologies to control the delivery of peptides from live sources.  Of note are 
anecdotal comments that reliance on entirely automated technological solutions to deliver 
insulin can deskill patients who then find it difficult to take over if the technology fails.  
Smart insulins  
Several glucose-responsive insulin delivery systems (so-called smart insulins) have been developed to 
release insulin from an implanted depot, circulating macromolecule or nanoparticles in proportion to 
the circulating concentration of glucose by a direct chemical reaction.  Boronc acid derivatives have 
been particularly useful in this respect because glucose binds across two boronate molecules to form a 
bis-boronate complex.  So if insulin is loaded into a hydrogel containing large polymers to which 
boronates are attached, glucose will deform the polymer or increase cross-links and squeeze out the 
insulin in proportion to the amount of glucose. Alternatively, if the insulin is linked to boronic acid-
containing polymers, this can be displaced by glucose [25, 26].   Indeed, insulin analogues linked to 
7 
 
boronic acid deivatives via a fatty acid chain provided a glucose-responsive mechanism to release 
insulin which achieved more effective glycaemic control than unlinked insulin analogues in diabetic 
mice [27].  
Another approach with proof of principle in preclinical studies has utilised glucose oxidase within 
layers of polymers that coat implanted insulin-loaded vesicles.  Interaction with glucose causes the 
glucose oxidase to produce glucono-lactone which alters the integrity of the polymers and releases 
insulin [28] .  Similarly, injectable microgels containing glucose oxidase and loaded with insulin in a 
pH-responsive chitosan matrix will swell and release insulin in proportion to the protonation as 
glucose is oxidised [29].   A glucose oxidase-based insulin release system has also been incorporated 
into a transdermal patch with microneedles that penetrate subcutaneously.  The microneedles deliver 
polymeric vesicles incorporating glucose oxidase and insulin.  The insulin is released through an 
effect of hydrogen peroxide produced by the interaction of glucose with the glucose oxidase [30].   
Mixtures of peptides  
The inclusion of more than one peptide within a single injection dates from the late 1950s when 
premix insulins were introduced.   A biphasic action profile of these mixtures is achieved using an 
acetate buffer suitable for a protamine-insulin with no excess of zinc (intermediate-acting time course) 
and an excess of free insulin (soluble rapid-acting or short-acting) which remains separate.   Given as 
a single subcutaneous injection the rapid- or short-acting component provides a prompt rise of insulin 
concentrations to address the blood glucose excursion from an immediate meal, while the 
intermediate-acting component provides basal insulinisation for a longer period between meals. 
Different proportions of rapid- or short-acting free insulin together with intermediate-acting 
protamine-insulin are available, and it is pertinent to note the transAtlantic nomenclature discrepancy 
where the short-acting component is written first in Europe (ie, a 30/70 mix refers to 30% short-acting 
and 70% intermediate-acting), whereas in North America the long-acting component is written first.   
Although still used extensively in some regions of the globe, premix insulins are being superseded by 
basal-bolus regimens in which a daily injection of a long-acting insulin is accompanied by 
administration of rapid- or short-acting insulin with dose adjustment to suit timing, composition and 
size of individual meals [6].  
In some regions there has been limited specialist use of a combination of the amylin analogue 
pramlintide with insulin to improve prandial glycamic control by slowing gastric emptying, increasing 
satiety, assisting weight control and reducing glucagon [31].  However the pramlintide and insulin are 
not mixed together in the same syringe [32]. Preparing stable mixtures of peptides with different 
physicochemical properties, particularly different solubility characteristics, poses a considerable 
challenge. However, mixtures of insulin with a GLP-1 receptor agonist (GLP-1RA) have been 
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developed and used effectively in patients with type 2 diabetes [33].  These two different classes of 
agents offer complementary actions, such that the GLP-1RA can provide additional glucose-lowering 
by potentiating glucose-dependent insulin secretion and suppressing glucagon secretion.  The satiety 
effect of GLP-1RAs can also off-set the weight gain associated with insulin therapy [34].  
IDegLira is a fixed‐ratio combination of the long-acting insulin degludec with the GLP-1RA  
liraglutide in the ratio 100 units insulin with 3.6 mg/ml liraglutide.  The combination is delivered via a 
pen device as a single daily subcutaneous injection titrated in the same way as for insulin.  In a 1 year 
clinical trial in type 2 diabetes,  IDegLira reduced HbA1c (by 1.84%) more than degludec alone (by 
1.40%) or liraglutide alone (by 1.21%).  IDegLira also prevented the weight gain associated with the 
insulin component alone, and achieved a greater reduction of HbA1c with a lower daily amount of 
insulin (39 units with IDegLira versus 62 units with degludec) and fewer episodes of hypoglycaemia 
[35].  Fixed-ratio combinations of the basal insulin glargine with the GLP-1RA lixisenatide 
(IGlarLixi) have also been developed in ratios of 2 or 3 units of glargine to 1 ug of lixisenatide.  
Compared with insulin glargine alone, IGlarLixi produced greater reductions of HbA1c with lower 
daily amounts of insulin, lower risk of hypoglycaemia and without weight gain in type 2 diabetes 
patients, similarly to IDegLira [36, 37].   
Hybrid and chimeric peptides 
Preclinical studies have provided evidence that separate injections of GLP-1 and other selected gluco-
regulatory peptides can assist metabolic control, and this has prompted the development of hybrid 
molecules [38}.  For example, GLP-1 has been linked with gastrin to improve beta-cell mass, or with 
glucagon to improve energy expenditure and satiety [39, 40].  However, if a combination of two 
peptides with complementary actions can be used in a single injection, what are the opportunities for 
mixtures of three or more peptides?   Three differently acting oral (non-peptide) glucose-lowering 
agents or one or two oral agents with one or two injectable agents (insulin and/or a GLP-1RA) are 
sometimes used in advanced insulin resistant and insulinopenic stages of type 2 diabetes [2].    
The prospect of improving the management of type 2 diabetes with multiple peptides in the same 
injection has encouraged the development of chimeric peptides, and a dual-action chimeric peptide 
with an intermixed sequence of GLP-1 and GIP has been shown to exert glucose-lowering and insulin 
releasing effects in obese-diabetic rodent models, cynomolgus monkeys and humans [41].  Recently 
the chimeric concept has been taken from two to three agonist actions with the construction of novel 
amino acid sequences that enable interaction with GLP-1 plus GIP plus glucagon [42, 43].  For 
example a DPP-4 resistant GLP-1 analogue which was modified to activate receptors for GLP-1, GIP 
and glucagon ([dA(2)]GLP-1/GcG) lowered plasma glucose in insulin resistant obese-diabetic (ob/ob) 
mice and high fat-fed mice, the latter also showing weight reduction [42].  Another triple-acting 
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chimeric peptide with agonist effects at the GLP-1, GIP and glucagon receptors, and without cross-
reactivity at other related receptors has been reported to reduce body weight, improve glycaemic 
control, decrease excess liver fat, supress food intake and increase energy expenditure in rodent 
models [43].  Thus, in addition to enhancing the incretin effect and improving glycaemic control, 
chimeric peptides can be structured to address the obesity that frequently accompanies type 2 diabetes 
and contributes to the insulin resistance and other co-morbidities [44].  The balance of activities 
requires the glucose-lowering effect of GLP-1 to predominate over the potential for glucagon to raise 
blood glucose, while effects mediated through receptors for both of these peptide can reduce caloric 
intake and glucagon can improve energy expenditure.  Although GIP promotes nutrient-mediated 
insulin release it can also enhance glucagon secretion and exert variable effects on body composition 
in different metabolic circumstances, emphasising the importance of achieving an appropriate balance 
between the three receptor interactions.   
Depot GLP-1 
Limited adherence to peptide injection regimens may significantly compromise their potential benefits 
[45]. Whereas the detrimental effects of missed insulin injections are soon manifest in poor health, 
reduced adherence to administration schedules for GLP-1RAs are less easily recognised, and longer 
acting may help to obviate adherence issues associated with frequent injections.  The protracted 
effects of GLP-1RAs reduce hyperglycaemia without causing hypoglycaemia, facilitate weight 
reduction, appear to protect pancreatic beta cells from apoptosis and may reduce CV risk in type 2 
diabetes [46, 47].  A depot technology giving continuous delivery of exenatide is a match stick-sized 
subcutaneously implanted miniature osmotic pump (ITCA 650) which maintains therapeutic 
concentrations and sustains glycaemic efficacy with HbA1c reductions of >1.4% (15 mmol/mol) for 
up to 2 years [48, 49].  The device is readily implanted and removed intact, and although 19% of 
patients initially developed anti-exenatide antibodies, the antibody titres subsequently declined and 
were only measurable in 2.8% of patients by 2 years and did not appear to be directed against the 
active site of exenatide.  A particularly interesting feature of the device is the storage of sufficient 
exenatide into such a small volume and to remain biologically patent during implantation for 2 years.  
It is anticipated that the device could soon become available for routine clinical use and should 
provide an opportunity to improve adherence by obviating repeated injections.  
An early concept type of GLP-1RA depot uses a subcutaneously injected soluble fusion protein ELP 
(elastin-like-polypeptide) to form a gel at body temperature [50].  The ELP is linked to oligomers of a 
GLP-1 analogue with an Ala8 to Gly substitution for DPP-4 resistance and a Gly22 to Glu 
substitution to stabilize the α-helix. Monomers are separated by a Gly-Ala dipeptide added to the N-
terminus and an Arg added at the C-terminus.  This enables monomers to be released by local 
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arginine-specific proteases and then activated by DPP-4 (dipepidyl peptidase-4) which cleaves the N-
terminal Gly-Ala to leave the active GLP-1 analogue.  Thus, this so-called POD (protease operated 
depot) takes advantage of endogenous DPP-4 to isolate the active GLP-1 analogue without causing 
GLP-1 degradation, and its ability to maintain release of the GLP-1 has been demonstrated over 5days 
in mice.  
Other peptides 
Beyond the examples considered above, several further gluco-regulatory peptides exert effects that 
could be harnessed therapeutically to improve glycaemic and related disturbances in type 2 diabetes 
[51].   These are considered in detail in subsequent articles in this issue of Peptides, but it is 
appropriate to comment briefly here [Table 1].   
The relative hyperglucagonaemia of type 2 diabetes presents a particular therapeutic conundrum 
because the production of glucagon can be suppressed and the action interrupted, but compensatory 
mechanisms are then invoked and the counter-regulatory response of glucagon during hypoglycaemia 
can be vital [52, 53].   That said, glucagon promotes appetite control and energy expenditure and 
provides a convenient foundation sequence of amino acids for chimeric constructs [42].  Although 
GLP-1 and GIP can be exploited therapeutically to modulate glycaemic control, additional hormones 
from the alimentary tract have shown therapeutic potential in early clinical studies. Oxyntomodululin 
has attracted interest because it interacts with GLP-1 and glucagon receptors to reduce feeding, 
increase energy expenditure and reduce body weight while lowering blood glucose in type 2 diabetes 
[54, 55].  The satiety and weight-reducing effects of peptide YY, ghrelin antagonists and 
cholecystokinin analogues are being examined for the treatment of obesity [56-58], and emerging 
evidence from bariatric procedures may reveal additional intestinal peptides with therapeutic potential 
in type 2 diabetes [59].   
Adipose tissue continues to provide peptides with gluco-regulatory effects that could be utilised for 
therapeutic purposes. The appetite-suppressing, weight-lowering and metabolic effects of metraleptin 
have been explored extensively but have therapeutic limitations due to escalating leptin resistance 
[60].  The weight-lowering and insulin-sensitising properties of adiponectin are attractive, but given 
the physicochemical properties of adiponectin, non-peptide modulation of adiponectin receptors may 
be more practicable for therapeutic purposes in type 2 diabetes [61].  Many other adipokines, 
including resistin, retinol-binding proteim-4, omentin, visfatin and apelin have been noted as possible 
targets for future peptide therapeutics in type 2 diabetes [51], and fibroblast growth factor 21 (FGF21) 
derived from adipose tissue and other organs has entered clinical study [62]. Peptides from other 
sources, such as fetuin from liver and irisin from muscle are emerging as prospective therapeutic 
targets, and there remains untapped potential to examine the activities of brain neurotransmitter 
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peptides.  Comparative endocrinology has already informed diabetes therapeutics with a novel peptide 
(exendin-4 from the gila monster, Heloderma suspectum), and identified many other new peptides 
with gluco-regulatory potential, indicating the diversity of leads from which peptide therapies can 
arise [63, 64].      
Peptide opportunities  
As illustrated by the foregoing examples, peptides offer a spectrum of potential therapeutic 
opportunities to improve blood glucose control in type 2 diabetes. Because many peptides are known 
to contribute to normal glucose homeostasis, and disturbances in the secretion and/or action of several 
of these peptides are pivotal in the development and progression of type 2 diabetes, a selection of 
peptide-dependent targets is recognised. Peptides are highly selective in their actions at defined 
receptors and can be structurally modified for desired adjustments to their pharmacokinetic and 
pharmacodynamic properties. When administered as natural replacements they are generally well 
tolerated and have good safety profiles when used judiciously with attention to dose, timing, and 
consideration of co-morbidities and potential drug interactions.  
Commercial production methods which mostly include recombinant DNA introduced into bacterial or 
fungal cultures, are economically viable with predictable purity, consistency and sterility during 
storage, distribution and usage by healthcare professionals and patient self-administration. Many 
different devices facilitate measured and comfortable administration, including dose-dialled pen 
devices with timing records and alerts as well as pumps and skin patches. Formulations for enteral and 
inhaled delivery have received extensive investigation, and although unsuccessful to date they remain 
interesting opportunities. Smart molecules that are self-regulating offer an exciting potential 
alternative to cell-based therapies. Advancing knowledge of the secondary and tertiary structures of 
peptide hormones and their receptor binding sites has fostered burgeoning libraries of structures with 
defined receptor binding and activity profiles which focus opportunities to construct peptides (eg 
chimeric) with selected epitopes for particular functions. As capability grows to amalgamate multiple 
therapies into a single peptide it is anticipated that future medicines will be able to take advantage of 
insights from proteomics, metabolomics and pharmacogenomics to tailor such peptides to individual 
needs.  Combining epitopes of multiple peptide agonists into a single designer peptide offers the 
potential to simultaneously address a variety of therapeutic targets to suit the individual patient and to 
circumvent many of the physico-chemical differences that detract from the combination of individual 
peptides in a single injection. 
Peptide challenges 
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Significant challenges continue to face the therapeutic application of peptide including their design, 
production and administration, through to their distribution within the body and their degradation.  
Ongoing basic research into structure-function events at the cellular level, especially interactions of 
peptides with receptors and the control of receptor function and post-receptor pathways, should 
inform the future design of hormonal peptides to achieve particular physiological effects.  A recent 
example of the importance of this research is the crystallographic determination of the binding of 
insulin at its receptor to initiate the conformational adjustments that enable the intracellular extension 
of the receptor to operate as a kinase enzyme [65, 66]. This has opened a new avenue of exploration 
into the design of molecules to mimic all or part of this process, which (peptide enthusiasts may see 
ironically) as a vision that could enable smaller non-peptide molecules to duplicate some of the 
therapeutic functions of insulin [67].  Initial research with non-peptide agonists at the GLP-1 and 
adiponectin receptors, and non-peptide glucagon receptor antagonists have also shown promise, but 
this approach is still in its infancy [51]. While non-peptide molecules are more easily produced and 
administered, they do not offer the possibility to construct multifunctional molecules that exert a 
selected variety of effects at several different receptors.  
Since the production of large peptides usually involves living organisms and multiple steps for 
isolation, purification, characterisation and formulation, there are very considerable commercial 
challenges to provide a consistent quality product with guaranteed sterility and an adequate shelf-life. 
This in turn is reflected in availability and price, fuelling economic deliberations over cost versus 
value, even when lives are at stake. Various physicochemical complexities continue to impinge, most 
notably stability before and after administration.    
With regard to administration, most of the obstacles that confront the use of peptides in diabetes apply 
to peptide therapies in general, but diabetes imposes extra difficulties due to the tight constraints on 
blood glucose concentrations and the rapidity and extent of fluctuations in glucose supply and 
demand. Although the timing and choice of dose for any therapy can be paramount, an ability to stop 
or reverse an adverse effect and prevent an over-effect remains a continual challenge for the treatment 
of diabetes. Avoiding hypos and other safety requirements, including the minimisation of CV risk 
must take account of the prospect that a therapy might be required for many years and maybe for life.  
Moreover, use of some peptides may be restricted by the comorbidities of diabetes, particularly 
impaired kidney and liver functions which are prevalent in diabetes and alter the pharmacokinetics of 
peptide therapies.  Type 2 diabetes patients often require a large number of medications which 
increases the risk of drug interactions: for example delayed gastric emptying with a GLP-1RA can 
alter the time course of oral medications.   
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Although further formulations and analogues with different periods of onset and durations of action 
will doubtless continue to address the time-sensitive nature of glycaemic control, basal insulin and 
GLP-1RAs can be delivered without rapid fluctuations: the former provide an approximately constant 
non-prandial low concentration of insulin and the latter can reduce hyperglycaemia without 
precipitating hypoglycaemia during inter-prandial periods.  Hence these peptides lend themselves to 
slow release formulations, for example by attachment to albumin, or transdermal or oral 
administration.  However, methods to improve oral delivery, avoiding proteolysis and accommodating 
vast changes of pH within the GI tract remain a formidable task. Current methods to enhance 
bioavailability with absorption enhancers, such as used for the gastric uptake of semaglutide, require 
periods with an empty stomach which can interrupt normal feeding patterns. Excess active peptides in 
the lymphatic drainage of the gut and incomplete intestinal absorption resulting in active peptides in 
the colon also raise questions and cautions.    
Immunogenicity applies particularly to analogues of natural peptides and especially to ‘designer’ 
constructs with much reduced homology compared to native structures.  Antibody production can 
vary greatly and unpredictably between individuals, and the risk of a catastrophic acute reaction must 
be appreciated.  However, overall this review provides evidence that with appropriate benefit-risk 
discretion, further advances in peptide therapeutics offer the potential to address a breadth of 
metabolic and associated morbidities in type 2 diabetes.   
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Figure 1. 
Type 2 diabetes is a progressive and variable disease in which substantial disturbances of insulin 
action and secretion have usually occurred before diagnosis.    The disease arises through multiple 
genetic factors (eg ethnic, body composition, expression levels of enzymes and transporters affecting 
nutrient metabolism) which interact with multiple environmental factors (eg quality and quantity of 
the diet, physical exercise, co-morbid conditions and medications), which accounts for the 
heterogeneity of the disease.  Male gender, increased parity and gestational diabetes amongst women, 
family history of diabetes and obesity are known to increase the risk of diabetes.  An early feature of 
the pathogenic process is a gradual reduction of insulin action (insulin resistance) that is initially 
compensated by increased insulin secretion.  When the increased insulin concentrations are unable to 
fully compensate for the insulin resistance there is a rise in postprandial glucose concentrations and 
later fasting glucose concentrations referred to as impaired glucose tolerance (IGT) and impaired 
fasting glucose (IFG) respectively. This is associated with a decline or delay in the initial (first phase) 
secretion of insulin in response to a prandial rise in blood glucose, although the second phase of 
insulin secretion is usually accentuated.   The usual rhythm of insulin secretion is lost and increased 
proportions of proinsulin and incompletely processed proinsulin, which have less biological activity 
than insulin, are released by the ‘stressed’ beta cells.  Excess adiposity aggravates insulin resistance 
through altered lipid supply and the release of pro-inflammatory adipokines.   If, in presence of 
insulin resistance, the secretory function of the ‘stressed’ beta cell population declines, the condition 
of IGT/IFG progresses into type 2 diabetes, and a continued deterioration of beta cell function and 
mass gives rise to escalating hyperglycaemia.  Concurrent changes to the secretion and action of other 
gluco-regulatory peptides contribute to the rising hyperglycaemia, notably a relative 
hyperglucagonaemia and impaired action of GLP-1.  
 
Figure 2. 
Inadequate blood glucose control in type 2 diabetes involves disturbances of many gluco-regulatory 
peptide hormones, including insulin, glucagon, incretins and other gastro-intestinal peptides, 
adipokines and neuro-endocrine peptides.  These provide a variety of different therapeutic targets 
through which current agents address the hyperglycaemia.  All treatment strategies are underpinned 
by lifestyle measures, notably diet, exercise and general health education, and pharmacological 
therapies are selected on an individualised basis to be commensurate with the changing circumstances 
of the patient as the disease progresses.  Metformin, which is usually the first-line drug choice in type 
2 diabetes counters insulin resistance, reducing hepatic glucose production and facilitating glucose 
utilisation. Sulfonylureas and meglitinides stimulate insulin secretion by pancreatic beta cells. 
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Dipeptidyl peptidase-4 (DPP-4) inhibitors slow the degradation of the main incretin hormones 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) thereby 
enhancing their effects.  GLP-1 receptor agonists (GLP-1RAs) are GLP-1 analogues which mimic the 
effects of GLP-1 to potentiate glucose-dependent insulin secretion, reduce glucagon secretion by 
pancreatic alpha cells, delay gastric emptying and exert a satiety effect.  Sodium-glucose co-
transporter-2 (SGLT2) inhibitors reduce glucose reabsorption by the kidney and increase loss of 
excess glucose in the urine.  Pioglitazone is a thiazolidinedione peroxisome proliferator-activated 
receptor- -sensitive adipocytes and 
improves insulin sensitivity. Acarbose inhibits intestinal alpha-glucosidase enzymes which slows the 
final stages of carbohydrate digestion, slowing the entry of glucose into the circulation.  In some 
countries (not Europe) glucose-lowering indications are approved for the bile acid sequestrant 
colesevelam, which may increase GLP-1 secretion from intestinal L-cells, and the dopamine receptor 
agonist bromocriptine, which triggers neural pathways to reduce hepatic glucose output. The amylin 
analogue pramlintide is also available in some regions as a supplement to insulin therapy to increase 
satiety, slow gastric emptying and reduce glucagon secretion.   Insulin is the essential therapy for type 
1 diabetes and usually the default therapy for advanced stages of type 2 diabetes when other agents 
are no longer adequately effective.  Insulin facilitates glucose uptake, storage and metabolism by 
muscle, reduces glucose production by liver, reduces lipolytic release of fatty acids from adipose 
tissue and exerts many other metabolic and cell-differentiating effects essential for life.    
 
Figure 3 
Concepts for ‘smart insulins’ using polymers containing boronic acid derivatives (eg, phenylboronic 
acid) embedded within a gel containing insulin. A. Glucose binds two boronates to produce a glucose-
bis-boronate complex.    B. Glucose-bis-boronate complexes deform the polymer with increased cross 
links that squeeze out insulin from the gel in proportion to the glucose concentration.   C.  
Alternatively if insulin is linked to boronate-containing polymers, the insulin can be displaced by 
interaction with glucose, releasing insulin in proportion to the glucose concentration.   Based on refs 
25 and 26. 
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Table 1.  Gluco-regulatory peptides with established or potential therapeutic use in the management of 
hyperglycaemia in type 2 diabetes.  ↑ increase;   ↓ decrease 
Peptide hormone  Main gluco-regulatory effects Type 2 diabetes therapeutic potential  
Pancreas 
Insulin ↓ Hepatic glucose output 
↑ Peripheral glucose uptake and 
utilization 
↓ Lipolysis 
↑ Protein anabolism  
↑ Growth and differentiation  
Lowers blood glucose but can cause 
hypoglycaemia. Default glucose-
lowering therapy in severely 
insulinopenic type 2 diabetes. Many 
available analogues, formulations and 
delivery systems. Extensive 
developments in progress 
Glucagon ↑ Hepatic glucose output 
↑ Energy expenditure 
↑ Satiety  
Raises blood glucose: key counter-
regulatory effect. Relative 
hyperglucagonaemia in type 2 
diabetes is potential therapeutic 
target.   
Somatostatin ↓ Glucagon and insulin secretion 
↓ Growth hormone secretion 
Many other neuro-endocrine roles, 
especially in GI tract  
Analogues used therapeutically to 
treat excess GH, but suppression of 
insulin reduces suitability for type 2 
diabetes 
Pancreatic 
polypeptide 
↓ Food intake  
Various GI effects  
Possible value in treatment of obesity 
Amylin (IAPP) ↑ Satiety 
↓ Gastric emptying 
↓ Glucagon secretion  
Analogue (pramlintide) available in 
some regions for use with insulin: 
assists glucose lowering and weight 
loss  
Alimentary tract 
GLP-1 ↑ Nutrient-induced insulin secretion 
↓ Glucagon secretion 
↓ Gastric emptying 
↑ Satiety and ↓ body weight 
Emerging CV and neuroprotective 
effects  
Established blood glucose-lowering 
therapy in overweight and obese type 
2 diabetes, especially with metformin 
and insulin.  Fixed ratio combinations 
with insulin 
GIP ↓ Gastric acid secretion 
↑ Nutrient-induced insulin secretion 
↑ Glucagon secretion 
Emerging roles in adipogenesis and 
Research into potential therapeutic 
role: effects of agonists and 
antagonists vary with physiological 
state. Potential therapeutic role 
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bone remodelling supported by bariatric procedures that 
reduce contact of food with 
duodenum 
Peptide YY ↓ Gastric emptying 
↑ Satiety and ↓ body weight 
Potential anti-obesity therapy 
Oxyntomodulin  ↑ Nutrient-induced insulin secretion 
↓ Gastric emptying 
↑ Energy expenditure 
↑ Satiety and ↓ body weight 
Overall effects on glucagon ?  
Emerging effects on liver and adipose 
tissue 
Potential therapy for type 2 diabetes.  
Agonist at receptors for GLP-1 and 
glucagon: uncertain balance of 
glucose lowering effect via GLP-1R 
versus glucose-raising effect via 
glucagon receptor. Possible ↓ ghrelin, 
↑adiponectin and ↑ FGF21 
Cholecystokinin  ↑ Gall bladder contraction  
↑ Pancreatic digestive enzymes  
↑ Satiety 
↓ Gastric emptying  
Various neural effects 
Fragments and analogues that 
preferentially promote satiety 
considered for therapeutic purposes. 
Possible effect on islet beta-cell 
growth  
Gastrin  ↑ Gastric acid secretion 
↑ Gastric motility 
Possible effect on islet beta-cell 
growth  
Secretin ↑ Pancreatic juice and enzymes Possible islet effects unclear 
Ghrelin ↑ Appetite 
↑ Adipogenesis 
↑ Growth hormone 
May decrease insulin secretion.  
Research into potential therapeutic 
role of antagonists  
Obestatin ↓ Appetite 
Emerging metabolic effects  
Therapeutic interest in possible effect 
on islet beta-cell growth and 
antagonism of ghrelin 
Adipose tissue 
Adiponectin ↑ Insulin sensitivity 
↑ Energy expenditure 
Various metabolic, anti-inflammatory 
and vascular effects 
Therapeutic application of 
adiponectin itself limited by 
physicochemical properties, but other 
agonists of adiponectin receptors and 
agents to stimulate adiponectin 
secretion being studied 
Leptin ↓ Appetite and ↓ body weight 
↑ Insulin sensitivity 
↑ Energy expenditure  
Neurally mediated effects that improve 
glucose homeostasis 
Short-term therapeutic value of 
metraleptin to reduce body weight 
and lower blood glucose is limited by 
increasing leptin resistance 
Resistin ↑ Insulin resistance ? 
 
Target candidate for antagonism ? 
Omentin ↑ Insulin sensitivity 
Emerging vascular effects ? 
 
Target candidate for agonism ? 
Visfatin Insulin-like effects ? Possible target candidate ? 
Apelin Emerging vascular and metabolic 
effects 
Possible target candidate ? 
Liver 
Fibroblast growth 
factor-21 
↑ Insulin sensitivity 
 
FGF-21 resistance may occur in 
obesity and type 2 diabetes 
Insulin-like growth 
factors 
Weak insulin-like effects  Assist glycaemic control if severe 
defects of insulin receptors 
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Fetuins Emerging evidence of impaired 
glycaemic control 
Possible target candidates ?   
Muscle  
Irisin ↑ Energy expenditure Possible target candidate ? 
 
Other peptide or amino acid-derived hormones such as those of the hypothalamus-pituitary, 
thyroid and adrenal medulla are involved in gluco-regulation but are not considered here as 
candidates for a specific therapeutic role in the management of hyperglycaemia in type 2 
diabetes. 
 
 
